TLR9 and STING agonists synergistically induce innate and adaptive type‐II IFN
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
TLR9 and STING agonists synergistically induce innate and adaptive type‐II IFN ; volume:45 ; number:4 ; year:2015 ; pages:1159-1169 ; extent:11
European journal of immunology ; 45, Heft 4 (2015), 1159-1169 (gesamt 11)
- Urheber
-
Temizoz, Burcu
Kuroda, Etsushi
Ohata, Keiichi
Jounai, Nao
Ozasa, Koji
Kobiyama, Kouji
Aoshi, Taiki
Ishii, Ken J.
- DOI
-
10.1002/eji.201445132
- URN
-
urn:nbn:de:101:1-2022112507103068356184
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:25 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Temizoz, Burcu
- Kuroda, Etsushi
- Ohata, Keiichi
- Jounai, Nao
- Ozasa, Koji
- Kobiyama, Kouji
- Aoshi, Taiki
- Ishii, Ken J.
Ähnliche Objekte (12)
Prediction of novel mouse TLR9 agonists using a random forest approach
Nanomaterial-encapsulated STING agonists for immune modulation in cancer therapy
A Purely Biomanufactured System for Delivering Nanoparticles and STING Agonists
Novel Poxin Stable cGAMP‐Derivatives Are Remarkable STING Agonists
EnanDIM - a novel family of L-nucleotide-protected TLR9 agonists for cancer immunotherapy
BAX as the mediator of C-MYC sensitizes acute lymphoblastic leukemia to TLR9 agonists
2’,4’‐LNA‐Functionalized 5′‐S‐Phosphorothioester CDNs as STING Agonists
A 2D Nanoradiosensitizer Enhances Radiotherapy and Delivers STING Agonists to Potentiate Cancer Immunotherapy
Bifunctional Metal–Organic Framework Synergistically Enhances Radiotherapy and Activates STING for Potent Cancer Radio‐Immunotherapy
Bifunctional Metal–Organic Framework Synergistically Enhances Radiotherapy and Activates STING for Potent Cancer Radio‐Immunotherapy
Responsive Multivesicular Polymeric Nanovaccines that Codeliver STING Agonists and Neoantigens for Combination Tumor Immunotherapy
MINCLE and TLR9 agonists synergize to induce Th1/Th17 vaccine memory and mucosal recall in mice and non-human primates
Prediction of novel mouse TLR9 agonists using a random forest approach
Nanomaterial-encapsulated STING agonists for immune modulation in cancer therapy
A Purely Biomanufactured System for Delivering Nanoparticles and STING Agonists
Novel Poxin Stable cGAMP‐Derivatives Are Remarkable STING Agonists
EnanDIM - a novel family of L-nucleotide-protected TLR9 agonists for cancer immunotherapy
BAX as the mediator of C-MYC sensitizes acute lymphoblastic leukemia to TLR9 agonists
2’,4’‐LNA‐Functionalized 5′‐S‐Phosphorothioester CDNs as STING Agonists
A 2D Nanoradiosensitizer Enhances Radiotherapy and Delivers STING Agonists to Potentiate Cancer Immunotherapy
Bifunctional Metal–Organic Framework Synergistically Enhances Radiotherapy and Activates STING for Potent Cancer Radio‐Immunotherapy
Bifunctional Metal–Organic Framework Synergistically Enhances Radiotherapy and Activates STING for Potent Cancer Radio‐Immunotherapy
Responsive Multivesicular Polymeric Nanovaccines that Codeliver STING Agonists and Neoantigens for Combination Tumor Immunotherapy
MINCLE and TLR9 agonists synergize to induce Th1/Th17 vaccine memory and mucosal recall in mice and non-human primates
Prediction of novel mouse TLR9 agonists using a random forest approach
Nanomaterial-encapsulated STING agonists for immune modulation in cancer therapy
A Purely Biomanufactured System for Delivering Nanoparticles and STING Agonists
Novel Poxin Stable cGAMP‐Derivatives Are Remarkable STING Agonists
EnanDIM - a novel family of L-nucleotide-protected TLR9 agonists for cancer immunotherapy
BAX as the mediator of C-MYC sensitizes acute lymphoblastic leukemia to TLR9 agonists
2’,4’‐LNA‐Functionalized 5′‐S‐Phosphorothioester CDNs as STING Agonists
A 2D Nanoradiosensitizer Enhances Radiotherapy and Delivers STING Agonists to Potentiate Cancer Immunotherapy
Bifunctional Metal–Organic Framework Synergistically Enhances Radiotherapy and Activates STING for Potent Cancer Radio‐Immunotherapy
Bifunctional Metal–Organic Framework Synergistically Enhances Radiotherapy and Activates STING for Potent Cancer Radio‐Immunotherapy
Responsive Multivesicular Polymeric Nanovaccines that Codeliver STING Agonists and Neoantigens for Combination Tumor Immunotherapy